Table 3.
Subgroup analysis for the effect of fibrates therapy on stoke, and fatal stroke
| |
Group |
Stroke event/total patients |
Relative risk (RR) |
P value |
Heterogeneity |
P value for heterogeneity |
|
|---|---|---|---|---|---|---|---|
| Fibrates | Placebo | ||||||
|
stroke |
Published years |
||||||
| |
after 2000 |
341/10062 |
351/10052 |
0.97 (0.84 to 1.13) |
0.72 |
0% |
0.51 |
| |
before 2000 |
292/8013 |
471/9664 |
1.06 (0.84 to 1.33) |
0.63 |
52% |
0.08 |
| |
Number of patients |
||||||
| |
≥1000 |
573/17689 |
775/19332 |
0.99 (0.87, 1.12) |
0.85 |
23% |
0.26 |
| |
<1000 |
60/386 |
47/384 |
1.23 (0.80, 1.90) |
0.34 |
30% |
0.24 |
| |
Mean age |
||||||
| |
<60 |
32/5331 |
27/5296 |
1.18 (0.71 to 1.96) |
0.53 |
- |
- |
| |
≥60 |
405/11326 |
439/11319 |
0.93 (0.80 to 1.08) |
0.34 |
17% |
0.30 |
| |
Gender |
||||||
| |
male |
329/8749 |
498/10401 |
1.09 (0.86 to 1.38) |
0.47 |
56% |
0.06 |
| |
Male/female |
304/9326 |
324/9315 |
0.95 (0.82 to 1.10) |
0.48 |
0% |
0.77 |
| |
Drug |
||||||
| |
clofibrate |
228/6749 |
383/8397 |
1.15 (0.98 to 1.34) |
0.08 |
0% |
0.59 |
| |
bezafibrate |
132/2331 |
126/2327 |
1.05 (0.80 to 1.38) |
0.37 |
21% |
0.26 |
| |
gemfibrozil |
64/1335 |
90/1339 |
0.72 (0.53 to 0.98) |
0.04 |
0% |
0.41 |
| |
fenofibrate |
209/7660 |
223/7653 |
0.94 (0.78 to 1.13) |
0.49 |
0% |
0.49 |
| |
Control |
||||||
| |
corn or olive oil |
55/5378 |
49/5344 |
1.11 (0.80 to 1.54) |
0.53 |
0% |
0.76 |
| |
placebo |
572/12697 |
761/14372 |
1.02 (0.88 to 1.17) |
0.83 |
32% |
0.17 |
| |
Follow-up |
||||||
| |
≥60 months |
421/12924 |
612/14575 |
1.01 (0.90 to 1.14) |
0.85 |
0% |
0.62 |
| |
<60 months |
212/5151 |
210/5141 |
1.05 (0.76 to 1.46) |
0.75 |
59% |
0.05 |
| |
Total cholesterol |
||||||
| |
≥6.0 mmol/L |
228/6749 |
383/8397 |
1.15 (0.98 to 1.34) |
0.08 |
0% |
0.59 |
| |
<6.0 mmol/L |
405/11326 |
439/11319 |
0.93 (0.80 to 1.08) |
0.34 |
17% |
0.30 |
| |
Total cholesterol lowering |
||||||
| |
≥5% |
409/12230 |
586/13890 |
1.04 (0.92 to 1.18) |
0.49 |
0% |
0.51 |
| |
<5% |
173/3080 |
188/3073 |
0.98 (0.67 to 1.45) |
0.93 |
71% |
0.03 |
| |
Triglyceride lowering |
||||||
| |
≥30% |
101/1603 |
113/1603 |
0.96 (0.46 to 1.99) |
0.92 |
74% |
0.02 |
| |
<30% |
477/11094 |
660/12769 |
1.02 (0.91 to 1.15) |
0.69 |
0% |
0.51 |
| |
Pre-exsistent diseases |
||||||
| |
stroke |
60/315 |
45/312 |
1.28 (0.86 to 1.90) |
0.23 |
35% |
0.22 |
| |
diabetes |
209/7660 |
223/7653 |
0.94 (0.78 to 1.13) |
0.49 |
0% |
0.49 |
| |
other |
364/10100 |
554/11751 |
1.00 (0.83 to 1.20) |
0.99 |
36% |
0.16 |
| |
Jadad score |
||||||
| |
4 |
481/11575 |
699/13251 |
0.95 (0.82 to 1.09) |
0.48 |
30% |
0.22 |
| |
<4 |
152/6500 |
123/6465 |
1.22 (0.98 to 1.52) |
0.07 |
0% |
0.58 |
| |
Overall |
633/18075 |
822/19716 |
1.02 (0.90 to 1.16) |
0.78 |
27% |
0.20 |
|
Fatal stroke |
Published years |
||||||
| |
after 2000 |
17/3548 |
17/3538 |
0.93 (0.33 to 2.60) |
0.89 |
51% |
0.15 |
| |
before 2000 |
24/6910 |
35/6875 |
0.70 (0.41 to 1.19) |
0.18 |
0% |
0.47 |
| |
Number of patients |
||||||
| |
≥1000 |
34/10143 |
40/10101 |
0.82 (0.45 to 1.48) |
0.51 |
32% |
0.22 |
| |
<1000 |
7/315 |
12/312 |
0.59 (0.23 to 1.47) |
0.26 |
0% |
0.59 |
| |
Mean age |
||||||
| |
<60 |
14/5331 |
14/5296 |
0.99 (0.47 to 2.08) |
0.99 |
- |
- |
| |
≥60 |
20/4812 |
26/4805 |
0.69 (0.27 to 1.75) |
0.44 |
53% |
0.12 |
| |
Gender |
||||||
| |
male |
35/7646 |
39/7612 |
0.89 (0.53 to 1.51) |
0.67 |
19% |
0.30 |
| |
Male/female |
6/2812 |
13/2801 |
0.46 (0.18 to 1.21) |
0.12 |
0% |
0.85 |
| |
Drug |
||||||
| |
clofibrate |
21/5646 |
26/5608 |
0.81 (0.45 to 1.44) |
0.47 |
0% |
0.59 |
| |
bezafibrate |
13/783 |
9/785 |
1.45 (0.62 to 3.37) |
0.39 |
- |
- |
| |
gemfibrozil |
3/1264 |
9/1267 |
0.33 (0.09 to 1.23) |
0.10 |
- |
- |
| |
fenofibrate |
4/2765 |
8/2753 |
0.50 (0.15 to 1.65) |
0.25 |
- |
- |
| |
Control |
||||||
| |
corn or olive oil |
16/5378 |
19/5344 |
0.85 (0.43 to 1.66) |
0.63 |
0% |
0.32 |
| |
placebo |
25/5151 |
33/5141 |
0.73 (0.38 to 1.40) |
0.34 |
30% |
0.23 |
| |
Follow-up |
||||||
| |
≥60 months |
16/5378 |
19/5344 |
0.85 (0.43 to 1.66) |
0.63 |
0% |
0.32 |
| |
<60 months |
25/5080 |
33/5069 |
0.73 (0.38 to 1.40) |
0.34 |
30% |
0.23 |
| |
Total cholesterol |
||||||
| |
≥6.0 mmol/L |
21/5646 |
26/5608 |
0.81 (0.45 to 1.44) |
0.47 |
0% |
0.59 |
| |
<6.0 mmol/L |
20/4812 |
26/4805 |
0.69 (0.27 to 1.75) |
0.44 |
53% |
0.12 |
| |
Total cholesterol lowering |
||||||
| |
≥5% |
29/6161 |
28/6129 |
1.04 (0.62 to 1.76) |
0.87 |
0% |
0.38 |
| |
<5% |
8/1532 |
16/1531 |
0.51 (0.22 to 1.20) |
0.12 |
0% |
0.40 |
| |
Triglyceride lowering |
||||||
| |
≥30% |
8/1532 |
16/1531 |
0.51 (0.22 to 1.20) |
0.12 |
0% |
0.40 |
| |
<30% |
17/3548 |
17/3538 |
0.93 (0.33 to 2.60) |
0.89 |
51% |
0.15 |
| |
Pre-exsistent diseases |
||||||
| |
stroke |
7/315 |
12/312 |
0.59 (0.23 to 1.47) |
0.26 |
0% |
0.59 |
| |
diabetes |
4/2765 |
8/2753 |
0.50 (0.15 to 1.65) |
0.25 |
- |
- |
| |
other |
30/7378 |
32/7348 |
0.91 (0.45 to 1.83) |
0.78 |
42% |
0.18 |
| |
Jadad score |
||||||
| |
4 |
7/4029 |
17/4020 |
0.41 (0.17 to 1.00) |
0.05 |
0% |
0.66 |
| |
<4 |
34/6429 |
35/6393 |
0.97 (0.60 to 1.57) |
0.91 |
0% |
0.51 |
| Overall | 41/10458 | 52/10413 | 0.79 (0.51 to 1.23) | 0.30 | 6% | 0.38 | |